When Will Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) Turn A Profit?
S&P 500 Futures Rise In Premarket Trading; Workday, CAVA Group Lead
RNAi Market and Technologies Industry Report 2024, With Company Profiles of Major Players Including Alnylam Pharmaceuticals, Novartis, Thermo Fisher Scientific and Revvity
Alnylam Pharmaceuticals Insider Sold Shares Worth $4,200,000, According to a Recent SEC Filing
Alnylam Pharmaceuticals(ALNY.US) Officer Sells US$4.2 Million in Common Stock
Here's Why Alnylam Pharmaceuticals (ALNY) Surged in Q2
Form 144 | Alnylam Pharmaceuticals(ALNY.US) Officer Proposes to Sell 4.2 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Aug 20, $Alnylam Pharmaceuticals(ALNY.US)$ Officer Greenstreet Yvonne intends to sell 15,000 shares of its common stock on Aug 20, with a total market value of approximately $4
Investing in Alnylam Pharmaceuticals (NASDAQ:ALNY) Five Years Ago Would Have Delivered You a 234% Gain
H.C. Wainwright Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Maintains Target Price $400
Express News | HC Wainwright & Co. Reiterates Buy on Alnylam Pharmaceuticals, Maintains $400 Price Target
UBS Raises Alnylam Pharmaceuticals' Price Target to $308 From $288, Buy Rating Maintained
Alnylam Pharmaceuticals Analyst Ratings
Goldman Sachs Upgrades Alnylam Pharmaceuticals(ALNY.US) to Buy Rating, Raises Target Price to $370
Buy Rating Affirmed for Alnylam Pharmaceuticals on Strong Amvuttra Trial Results and Robust Market Potential
Alnylam Pharmaceuticals(ALNY.US) Officer Sells US$5.97 Million in Common Stock
Is There An Opportunity With Alnylam Pharmaceuticals, Inc.'s (NASDAQ:ALNY) 47% Undervaluation?
BMO Capital Maintains Alnylam Pharmaceuticals(ALNY.US) With Buy Rating, Raises Target Price to $300
10 Health Care Stocks With Whale Alerts In Today's Session
Piper Lists Eight Defensive Biotechs to Face Market Volatility
The GLP-1 Makers to Add to Your Portfolio: Tema ETFs CEO